Spondyloarthritis & psoriatic arthritis
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice
Authors' conclusion
In this large European real-world study of axSpA and PsA patients treated with secukinumab, we demonstrate for the first time a comparable effectiveness in PRO remission and treatment retention rates between these two conditions when adjusted for confounders.
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) from 16 European registries initiating secukinumab in routine care
- Participants
- 3,087 vs 3,246
- Exposure
- axSpA vs PsA patients initiating secukinumab
- axSpAn = 3,087
- PsAn = 3,246reference
- Outcome
- Patient-reported outcomes (PRO) remission (pain, fatigue, PGA ≤2 on Numeric Rating Scale (NRS) 0-10 and HAQ ≤0.5) and 24-month retention rates
- Follow-up
- 6, 12 and 24 months
Methodological details16 European registries, routine care, LUNDEX adjustment for drug adherence, logistic regression, Kaplan-Meier and Cox regression
- 16 European registries
- Routine care
- LUNDEX adjustment for drug adherence
- Logistic regression
- Kaplan-Meier and Cox regression
Main finding
As reported in the abstract
PRO remission rates (pain, fatigue, PGA, HAQ)
- Crude pain, fatigue, Patient Global Assessment (PGA) and Health Assessment Questionnaire (HAQ) remission rates higher in axSpA than in PsA
- LUNDEX-adjusted remission rates similar
- No differences between groups after adjustment for confounders
Observational data: associations, not effects.
Further findings
| Outcome | HR (95 % CI) | |
|---|---|---|
| Secukinumab retention · 24 monthsFully adjusted analyses | 0.92 (0.84–1.02) | |
| 0.512Hazard ratio (log scale) |
Secukinumab retention · 24 months
- Retention rates similar in axSpA vs PsA
Original publication
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice. Semin Arthritis Rheum. Published 26 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →